Truvada for PrEP. Gilead grilled at US congressional hearing
The USA is being charged $70 per pill for a drug, yet tax payers largely funded the research. Thanks to...
Read more about Truvada for PrEP. Gilead grilled at US congressional hearing
Activists file post-grant opposition challenging a patent preventing purchase of cheaper treatment for hepatitis C
GTPI has presented an argument to the Brazilian Patent Office (INPI) to invalidate the patent granted for the drug daclatasvir....
Read more about Activists file post-grant opposition challenging a patent preventing purchase of cheaper treatment for hepatitis C
Advocacy in Ukraine results in drastic price reduction for HIV drug, raltegravir
The All-Ukrainian Network of People Living with HIV/AIDS (the Network) has received an official letter from Merck, dated 15 March...
Read more about Advocacy in Ukraine results in drastic price reduction for HIV drug, raltegravir
Watching Brazil: In defence of democracy and human rights
Author: Andresa Porto – Political Scientist and member of GTPI. Now that the Brazilian government’s new party blocs have been...
Read more about Watching Brazil: In defence of democracy and human rights
Watching Brazil. New monthly column analyzing the impact of Bolsonaro’s politics on civil society and access to medicines
Author: Andresa Porto – Political Scientist and member of GTPI. Translated from Portuguese, original version here. This is the first...
Read more about Watching Brazil. New monthly column analyzing the impact of Bolsonaro’s politics on civil society and access to medicines
Action against AbbVie. Money that could treat HIV patients ‘goes up in smoke’ in Kiev
Activists gathered outside a Kiev Court to highlight the huge amount of money being wasted on an overpriced drug, due...
Read more about Action against AbbVie. Money that could treat HIV patients ‘goes up in smoke’ in Kiev
-
Looking back to build on our success. Making more medicines affordable in 2019
We’re gearing up for the next, expanded phase of our campaign. We’re determined that pharmaceutical companies and governments must #TreatPeopleRight...
Read more about Looking back to build on our success. Making more medicines affordable in 2019
Dr Amit Sengupta, a treatment activist who dedicated his life to universal access, dies age 60
We are deeply saddened by the loss of Dr Amit Sengupta, our friend, colleague, and an inspiring treatment activist who...
Read more about Dr Amit Sengupta, a treatment activist who dedicated his life to universal access, dies age 60
African civil society plans for regional collaboration in tackling intellectual property barriers
First published by KELIN. ‘This meeting gives me hope that we can build a solid movement across Eastern and Southern...
Read more about African civil society plans for regional collaboration in tackling intellectual property barriers
Overpatented, overpriced: How excessive pharmaceutical patenting is extending monopolies and driving up drug prices
This new report by our partner I-MAK analyzes the twelve best selling drugs in the United States and shows how...
Read more about Overpatented, overpriced: How excessive pharmaceutical patenting is extending monopolies and driving up drug prices